4.5 Review

The Related Metabolic Diseases and Treatments of Obesity

Journal

HEALTHCARE
Volume 10, Issue 9, Pages -

Publisher

MDPI
DOI: 10.3390/healthcare10091616

Keywords

obesity; comorbidities; molecular signaling pathways; treatment; drugs; clinical trials

Ask authors/readers for more resources

Obesity is a chronic disease affecting over 1 billion people worldwide, characterized by abnormal accumulation of body fat and commonly associated with other metabolic disorders. Factors such as sedentary lifestyle, overnutrition, genetic and environmental conditions contribute to the development of obesity. Various strategies for obesity management and treatment include exercise, dietary changes, surgery, and medications. Psychological management plays a significant role, especially for distressed patients. Gut microbiota has a crucial role in obesity and its associated conditions, and microbial reprogramming through methods like fecal microbiota transplantation shows promise. Prevention and early treatment of obesity are essential in preventing its progression to comorbidities.
Obesity is a chronic disease characterized by the abnormal or excessive accumulation of body fat, affecting more than 1 billion people worldwide. Obesity is commonly associated with other metabolic disorders, such as type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular diseases, chronic kidney disease, and cancers. Factors such as a sedentary lifestyle, overnutrition, socioeconomic status, and other environmental and genetic conditions can cause obesity. Many molecules and signaling pathways are involved in the pathogenesis of obesity, such as nuclear factor (NF)-kappa B, Toll-like receptors (TLRs), adhesion molecules, G protein-coupled receptors (GPCRs), programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1), and sirtuin 1 (SIRT1). Commonly used strategies of obesity management and treatment include exercise and dietary change or restriction for the early stage of obesity, bariatric surgery for server obesity, and Food and Drug Administration (FDA)-approved medicines such as semaglutide and liraglutide that can be used as monotherapy or as a synergistic treatment. In addition, psychological management, especially for patients with obesity and distress, is a good option. Gut microbiota plays an important role in obesity and its comorbidities, and gut microbial reprogramming by fecal microbiota transplantation (FMT), probiotics, prebiotics, or synbiotics shows promising potential in obesity and metabolic syndrome. Many clinical trials are ongoing to evaluate the therapeutic effects of different treatments. Currently, prevention and early treatment of obesity are the best options to prevent its progression to many comorbidities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available